Powered by

Is CRISPR Stock Heading to $160 in 2021?

Mar 04, 2021 - Nasdaq
Financial Results

CRISPR Therapeutics (NASDAQ: CRSP) is a stock with nearly 40% upside, according to a new analysis. Prognosticator Silvan Turkcan of JMP Group's JMP Securities has initiated coverage of the company with a market outperform (buy) recommendation at a $160 per share price target.

Gene editing, which is the core of CRISPR's business, is still a nascent industry with a great deal of potential. Turkcan described CRISPR's offerings as "powerful new bioengineering tools" that have a potentially ver...